Sanofi (SNY) Short term Debt (2009 - 2026)

Sanofi has disclosed Short term Debt across 18 years of filings, most recently posting $8.2 billion for Q2 2026.

• In Q2 2026, Short term Debt fell 1.29% year-over-year to $8.2 billion; the TTM figure through Jun 2026 stood at $8.2 billion (down 1.29% YoY), while the FY2025 annual figure was $5.1 billion, up 10.95% from the prior year.
• Short term Debt came in at $8.2 billion for Q2 2026 at Sanofi, up from $5.1 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.9 billion in Q2 2024 to a low of $2.2 billion in Q4 2023.
• Average Short term Debt over 5 years is $5.6 billion, with a median of $5.1 billion recorded in 2025.
• Year-over-year, Short term Debt slumped 48.33% in 2023 and jumped 104.41% in 2024.
• Over 5 years, Short term Debt stood at $4.3 billion in 2022, then plunged by 48.33% to $2.2 billion in 2023, then soared by 104.41% to $4.5 billion in 2024, then gained by 12.37% to $5.1 billion in 2025, then soared by 61.58% to $8.2 billion in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $8.2 billion in Q2 2026, $5.1 billion in Q4 2025, and $8.3 billion in Q2 2025.